InFocus Clinical Research is proud to announce its inclusion in
the 2024 Inc. 5000 list, ranking at No. 724 among the
fastest-growing private companies in America. This prestigious
recognition highlights InFocus's exceptional growth and commitment
to innovation in retina clinical trials.
NASHVILLE, Tenn. and NEW YORK, Aug. 15,
2024 /PRNewswire-PRWeb/ -- Inc. revealed today that
InFocus Clinical Research ranks No. 724 on the 2024 Inc. 5000, its
annual list of the fastest-growing private companies in America.
The prestigious ranking provides a data-driven look at the most
successful companies within the economy's most dynamic segment—its
independent, entrepreneurial businesses. Microsoft, Meta, Chobani,
Under Armour, Timberland, Oracle, Patagonia, and many other
household-name brands gained their first national exposure as
honorees on the Inc. 5000.
"It is a tremendous honor to be recognized as one of the
fastest-growing companies and the leading CRO in our field," said
Brad Doerschuk, InFocus Clinical
Research's CEO. "This recognition of InFocus's growth is a
testament to the unwavering dedication of our team and the trust of
our valued partners, united in our shared mission to cure
blindness."
The Inc. 5000 class of 2024 represents companies that have
driven rapid revenue growth while navigating inflationary pressure,
the rising costs of capital, and seemingly intractable hiring
challenges. Among this year's top 500 companies, the average median
three-year revenue growth rate is 1,637 percent. In all, this
year's Inc. 5000 companies have added 874,458 jobs to the economy
over the past three years.
For complete results of the Inc. 5000, including company
profiles and an interactive database that can be sorted by
industry, location, and other criteria, go to www.inc.com/inc5000.
All 5000 companies are featured on Inc.com starting Tuesday, August 13, and the top 500 appear in the
new issue of Inc. magazine, available on newsstands beginning
Tuesday, August 20.
"One of the greatest joys of my job is going through the Inc.
5000 list," says Mike Hofman, who
recently joined Inc. as editor-in-chief. "To see all of the
intriguing and surprising ways that companies are transforming
sectors, from health care and AI to apparel and pet food, is
fascinating for me as a journalist and storyteller. Congratulations
to this year's honorees, as well, for growing their businesses fast
despite the economic disruption we all faced over the past three
years, from supply chain woes to inflation to changes in the
workforce."
"I am immensely proud of our mission as the premier clinical
development partner advancing novel therapeutics for
vision-threatening disorders," said Doerschuk. "We are excited and
thankful for the continued opportunity to make a meaningful impact
on medicine, addressing long unmet needs for patients with retinal
diseases. While considerable progress has been made in the past
decade, we anticipate even greater advancements alongside our
continued growth in the years ahead."
About InFocus Clinical Research
The unique positioning of InFocus Clinical, as founded by global
retina stakeholders, ensures rapid integration of your protocol
with KOLs, key enrolling sites and, ultimately, the greatest
possible exposure of your product throughout development. The
InFocus Scientific Advisory Board is comprised of the most proven
and respected retina specialists. The fact InFocus is not just
therapeutically aligned but focused, with proprietary and
unprecedented staff training, ensures our staff are the most
knowledgeable and your product is developed with superior
efficiency and commitment.
Media Contact
Alexa Erazo, InFocus Clinical
Research, 1 6153128295, aerazo@infocusclinical.com,
https://www.infocusclinical.com/
View original
content:https://www.prweb.com/releases/infocus-clinical-research-ranks-no-724-on-the-2024-inc-5000-list-302223239.html
SOURCE InFocus Clinical Research